Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 1, 2005, Pages 14-18

  Siziopikou, Kalliopi P ^a   Khan, Saba ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; bcl 2; bcl x L; DCIS; HER2

Indexed keywords

APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CARCINOMA IN SITU; DATA ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC CORRELATION; HUMAN; IMMUNOHISTOCHEMISTRY; NECROSIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE AMPLIFICATION; GENES, BCL-2; GENES, ERBB-2; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 14144254083     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200503000-00003     Document Type: Article

References (38)

1. National Cancer Institute. Breast Cancer Stage Distribution, 1998. In: SEER Cancer Statistics Review, 1973-1998. Available at http:seer.cancer.gov. 2001.
2. Siziopikou KP, Prioleau JE, Harris JR, et al. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer. 1996;77:499-506.
3. Hokenbery DM, Zutter M, Hickey W, et al. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991;88:6961-6965.
4. Baer R. Bcl-2 breathes life into embryogenesis. Am J Pathol. 1994;145:7-10.
5. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539-542.
6. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
7. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-x-L, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567-1576.
8. Poruchynsky MS, Wang EE, Rudin CM, et al. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998;58:3331-3338.
9. Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch. 1997;430:17-22.
10. Siziopikou KP, Schnitt SJ. MIB-1 proliferation index in ductal carcinoma in situ of the breast: relationship to the expression of the apoptosis regulating proteins bcl-2 and p53. Breast J. 2000;6:400-406.
11. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
12. Thor AD, Berry DA, Budman DR, et al. erb-B-2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
13. Eisenhauer EA. From the molecule to the clinic - inhibiting HER2 to treat breast cancer. N Engl J Med. 2001;344:841-842.
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
15. Coon JS, Marcus E, Gupta-Bart S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
16. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1998;319:1239-1245.
17. Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990;3:449-454.
18. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 1990;21:1164-1167.
19. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11:167-180.
20. Chhieng DC, Ross JS, Ambras RA, et al. BCL-2 expression and the development of endometrial carcinoma. Mod Pathol. 1996;9:402-406.
21. Rao SK, Krishna M, Woda BA, et al. Immunohistochemical detection of bcl-2 protein in adenocarcinoma and non-neoplastic cellular compartments of the lung. Mod Pathol. 1996;9:555-559.
22. Mosnier JF, Perret AG, Vindimian M, et al. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Arch Pathol Lab Med. 1996;120:654-659.
23. Silvestrini R, Veneroni S, Diadone MG, et al. The bcl-2 protein: a prognostic indicator strongly related to the p-53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst. 1994;86:499-504.
24. Doglioni C, Dei Tos AP, Laurino L, et al. BCL-2 expression in breast carcinoma. Mod Pathol. 1994;7:15A.
25. Bhargava V, Kell DL, van de Rijn M, et al. BCL-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol. 1994;145:535-540.
26. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol. 1994;145:1191-1198.
27. Leek RD, Kaklamanis L, Pezzela F, et al. BCL-2 in normal human breast and carcinoma association with oestrogen receptor-positive, epidermal growth factor receptor negative tumors and in situ cancer. Br J Cancer. 1994;69:135-139.
28. Zhang G-J, Kimijima I, Onda M, et al. Tamoxifen induced apoptosis in breast cancer cells relates to down regulation of bcl-2, but not bax and bcl-xL, without alteration of p-53 protein levels. Clin Cancer Res. 1999;5:2971-2977.
29. Leung LK, Wang TT. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat. 1999;55:73-83.
30. Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer. 2003;39:622-630.
31. Krajewski S, Krajewska M, Shabik A, et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994;145:1323-1336.
32. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (Hercep test) and fluorescence in situ hybridization (FISH) for HER-2/neu in 426 breast carcinomas from 37 centers. J Pathol. 2003;199:418-423.
33. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10:720-727.
34. Couturier J, Vincent-Salomon A, Nicholas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000;13:1238-1243.
35. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
36. Jacobs TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol. 2000;113:251-258.
37. Tubbs RR, Stoler MH. The quality of HER-2/neu predictive immunohistochemistry: something FISHy? Mod Pathol. 2000;13:1-3.
38. Bilous M, Dowsett M, Henna W, et al. Current perspectives on HER-2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182.